Brett Zbar, MD, is a Managing Director and Global Head of General Atlantic’s Life Sciences sector. Before joining General Atlantic in 2020, Brett was a Managing Director at Foresite Capital, where he focused on backing leading healthcare entrepreneurs and companies at all stages. While at Foresite, Brett served as a board member or observer at multiple companies including ConnectiveRx, Kinnate Biopharma, ORIC Pharmaceuticals (IPO), Peloton Therapeutics (acquired), Pharvaris, Replimune (IPO), Signant Health, Turning Point Therapeutics (IPO) and VenatoRx Pharmaceuticals.
Prior to his role at Foresite Capital, Brett was a Partner at Aisling Capital, where he invested in Life Sciences companies developing and commercializing innovative healthcare products, services and technologies. Brett began his career in McKinsey & Company’s Pharmaceuticals and Medical Products practice and completed his internship in internal medicine on the Osler Medical Service at Johns Hopkins Hospital.
Brett is a member of the Technology Development Fund External Review Committee at Memorial Sloan Kettering Cancer Center as well as the Council for Foreign Relations. He also serves as a Strategic Portfolio Optimization Committee member for City of Hope National Medical Center, and as Vice Chairman of the Yale Alumni Fund. He is a Board Member for Centessa Pharmaceuticals and has previously served as a Board Observer with Pharvaris. Brett received his B.A. in Molecular Biophysics and Biochemistry and English from Yale University before earning his M.D. from Harvard Medical School.
